Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib.
Lamarca, Angela Abdel-Rahman, Omar Salu, I McNamara, Mairéad G Valle, Juan W Hubner, Richard A
Lamarca, Angela
Abdel-Rahman, Omar
Salu, I
McNamara, Mairéad G
Valle, Juan W
Hubner, Richard A
Citations
Altmetric:
Abstract
Identification of patients with advanced HCC-deriving preferential benefit from sorafenib is desirable, and treatment-related adverse events are potential clinical biomarkers.
Description
Date
2016-08-19
Publisher
Collections
Keywords
Type
Article
Citation
Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib. 2016: Clin Transl Oncol